Drug major Lupin today announced the launch of Desoximetasone Topical Spray, used for the treatment of plaque psoriasis, in the US market.
“Lupin’s Desoximetasone Topical Spray, 0.25 per cent, is the generic equivalent of Taro Pharmaceuticals USA Inc’s Topicort Topical Spray, 0.25 per cent. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older,” the company said in a regulatory filing.
Quoting IQVIA MAT May 2018 data, Lupin said Desoximetasone Topical Spray, 0.25 per cent, had annual sales of approximately $18.7 million in the US. Shares of Lupin were trading 0.71 per cent higher at Rs 820.35 apiece on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.